S&P 500
5.064,20 +45,81 (+0,91%) Nasdaq
15.840,96 +235,48 (+1,51%) NIKKEI 225
38.236,07 -37,98 (-0,10%) Dólar/Euro
1,0738 +0,0010 (+0,10%) Petróleo Brent
83,92 +0,25 (+0,30%) Bitcoin EUR
55.524,29 +2.051,57 (+3,84%)
Pulmatrix, Inc. (PULM)
Después del cierre:
Pulmatrix, Inc.
36 Crosby Drive
Suite 100
Bedford, MA 01730
United States
781 357 2333
https://www.pulmatrix.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 22
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Teofilo David Raad MBA | President, CEO & Director | 577,72k | N/A | 1970 |
| Mr. Peter Ludlum CMA, MBA | Interim CFO and Principal Accounting & Financial Officer | 510,22k | N/A | 1955 |
| Dr. Alexander M. Klibanov Ph.D. | Founder | N/A | N/A | 1950 |
Descripción
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Pulmatrix, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
